{
    "clinical_study": {
        "@rank": "8181", 
        "arm_group": [
            {
                "arm_group_label": "Phentermine-Topiramate", 
                "arm_group_type": "Experimental", 
                "description": "Qualifying participants will be assigned either Phentermine-Topiramate or placebo for a minimum of 5 days."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Qualifying participants will be assigned to Phentermine-Topiramate or placebo for a minimum of 5 days."
            }
        ], 
        "brief_summary": {
            "textblock": "Our overall goal is to determine the effect of Phentermine and Topiramate on gastric\n      emptying, gastric accommodation, and satiety and satiation in obese participants."
        }, 
        "brief_title": "Peripheral Pharmacodynamics of Phentermine_Topiramate in Obese Patients", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "Investigators propose a randomized controlled trial of combination phentermine topiramate\n      versus placebo given orally for 10-15 days.  Dosing of 3.75/23 mg days 1-5, increased to\n      7.5/46 mg days 6-14.  Participants will be randomized according to a computer generated\n      randomization schedule generated by the study statistician's office and submitted to the\n      Mayo Clinic CTSA research pharmacy. Allocation will be concealed.  The study blind will be\n      retained until all the data on gastric emptying, accommodation, satiation and satiety have\n      been recorded and transmitted to the statistician for data lock."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA\n\n          -  Obese subjects with BMI> 30 Kg/m2: Otherwise healthy individuals who are not\n             currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal,\n             hematological, neurological, endocrine (other than hyperglycemia not requiring\n             medical therapy) and unstable psychiatric disease.\n\n          -  Age: 18-70 years\n\n          -  Gender: Men or women. Women of childbearing potential will have negative pregnancy\n             test before initiation of medication.\n\n        EXCLUSION CRITERIA\n\n          -  Weight >300 lbs which is the limit of safety for the SPECT scanner\n\n          -  Concomitant use of appetite suppressants (i.e. caffeine based or diethylpropion) or\n             orlistat (Xenical\u00ae)\n\n          -  Uncontrolled hypertension (Blood pressure greater than 160/90 mmHg)\n\n          -  Concentration of fasting glucose greater than 240 mg/dl\n\n          -  Concentration of triglycerides greater than 400 mg/dl\n\n          -  Type 1 Diabetes\n\n          -  use of anti-diabetic drugs other than metformin,\n\n          -  history of nephrolithiasis,\n\n          -  recurrent major depression, presence or history of suicidal behaviour or ideation\n             with intent to act, and current substantial depressive symptoms (Patient Health\n             Questionnaire [PHQ-9]21 total score \u226510).\n\n          -  Concomitant use of MAOI inhibitors (i.e. phenelzine, selegiline), serotonergic\n             agents, and other centrally acting appetite suppressants\n\n          -  Significant psychiatric dysfunction based upon screening with the Hospital Anxiety\n             and Depression Scale [HADS] self-administered alcoholism screening test (SAAST,\n             substance abuse) and the questionnaire on eating and weight patterns (binge eating\n             disorders and bulimia). If such a dysfunction is identified by a HADS score \u226511 in\n             any of the subscales or difficulties with substance or eating disorders, the\n             participant will be excluded and given a referral letter to his/her primary care\n             doctor for further appraisal and follow-up.\n\n          -  End stage renal disease or liver cirrhosis\n\n          -  Intake of medication that could interfere with the interpretation of the study or\n             cause drug interaction (i.e. ketoconazole, erythromycin).   Specifically, birth\n             control pill, estrogen replacement therapy, and thyroxine replacement are\n             permissible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834404", 
            "org_study_id": "13-000948"
        }, 
        "intervention": [
            {
                "arm_group_label": "Phentermine-Topiramate", 
                "description": "Qualifying participants will be assigned to either Phentermine-Topiramate or placebo for a minimum of 5 days.", 
                "intervention_name": "Phentermine-Topiramate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Qualifying participants will be assigned to either Phentermine-Topiramate or placebo for a minimum of 5 days.", 
                "intervention_name": "Matched-Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Phentermine", 
                "Topiramate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Obesity", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Peripheral Pharmacodynamics of Topiramate-Phentermine in Obese Patients", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Michael Camilleri, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoints for analysis of gastric function and satiation will be:\nT1/2  of gastric emptying of solids (scintigraphic transit of solid meal)\nFasting whole gastric volume (gastric accommodation testing)\nPostprandial whole gastric volume (gastric accommodation testing)\nMaximum volume of Ensure ingested (nutrient drink testing)\nCaloric intake from a standard buffet meal (buffet meal)\nGhrelin, GLP-1, CCK, PYY levels integrated over the 1.5 hours after the meal", 
            "measure": "Evaluate the effect of Phentermine-Topiramate vs placebo on gastric function and satiation in obese participants.", 
            "safety_issue": "No", 
            "time_frame": "Up to 30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834404"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Michael Camilleri", 
            "investigator_title": "Primary Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The secondary endpoints of  gastric transit, satiety and meal preferences will be:\nGastric residual at 2 and 4 hours (scintigraphic transit)\nT1/2  of gastric emptying of liquids (scintigraphic transit)\nAggregate symptom score 30 minutes after ingestion of Ensure(nutrient drink tests)\nIndividual postprandial symptom scores (nutrient drink testing)\nGhrelin, GLP-1, CCK, PYY change from baseline during the first 15 minutes after meal\nProportion of carbohydrate, fat and protein ingested at standard buffet meal (buffet meal)", 
            "measure": "Evaluate the secondary effects of Phentermine-Topiramate vs placebo in gastric transit, satiety and meal preferences in obese participants.", 
            "safety_issue": "No", 
            "time_frame": "Up to 30 days"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}